|
- 积分
- 218
- 威望
- 218
- 包包
- 260
|
本帖最后由 细胞海洋 于 2013-2-5 09:34 编辑 % d& F4 E( ?- j
( @& v" J- O7 t# n1 F0 s) xScience. 2013 Feb 1;339(6119):580-584.5 A ]8 j* K5 r2 v- y9 a! W, m
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition.
- s6 D% i+ Y5 i& i- S2 ]0 @Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, Concannon KF, Donaldson MC, Sequist LV, Brachtel E, Sgroi D, Baselga J, Ramaswamy S, Toner M, Haber DA, Maheswaran S.
6 E( [5 Q: u! `( T; VSource
3 U; X4 w% K% P5 |) nMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA.6 @, |5 j3 U3 p$ h% B$ [! h
Abstract, ?* s( \9 d+ s' O7 B' r/ o
Epithelial-mesenchymal transition (EMT) of adherent epithelial cells to a migratory mesenchymal state has been implicated in tumor metastasis in preclinical models. To investigate its role in human cancer, we characterized EMT in circulating tumor cells (CTCs) from breast cancer patients. Rare primary tumor cells simultaneously expressed mesenchymal and epithelial markers, but mesenchymal cells were highly enriched in CTCs. Serial CTC monitoring in 11 patients suggested an association of mesenchymal CTCs with disease progression. In an index patient, reversible shifts between these cell fates accompanied each cycle of response to therapy and disease progression. Mesenchymal CTCs occurred as both single cells and multicellular clusters, expressing known EMT regulators, including transforming growth factor (TGF)-β pathway components and the FOXC1 transcription factor. These data support a role for EMT in the blood-borne dissemination of human breast cancer.# }6 A% K* @, }4 X; J' O5 W
PMID: 23372014 [PubMed - as supplied by publisher] |
-
总评分: 威望 + 2
包包 + 10
查看全部评分
|
发表于 2013-2-4 15:49
